改良痘苗安卡拉(MVA)疫苗平台风险获益评估关键信息标准化模板
布莱顿协作组织病毒载体疫苗安全工作组(V3SWG)针对MVA-BN载体系统,综述其分子生物学特征并制定安全性信息收集模板。MVA-BN在鸡蛋中连续传代超过500次后减毒,不能在人类细胞中复制;多项临床试验中超过7800名受试者接种,安全性与其他现代获批疫苗一致,未发现炎症性心脏疾病信号。MVA-BN-Filo作为异源埃博拉疫苗方案组分已在欧盟获批,并在西非开展III期临床试验。
要点
- MVA-BN载体经500余次鸡胚传代减毒,无法在人类细胞中复制。
- MVA-BN骨架疫苗临床试验超7800人接种,安全性与其他现代疫苗一致。
- MVA-BN全程未发现炎症性心脏疾病信号,与复制型痘苗疫苗不同。
核心结论
- MVA-BN载体系统已获监管批准用于天花/猴痘疫苗及作为埃博拉疫苗方案组分,安全性良好。
- MVA-BN减毒特征明确,在免疫缺陷小鼠和非人灵长类中安全给药得到验证。
研究设计与样本
- 布莱顿协作组织病毒载体疫苗安全工作组(V3SWG)开展的综述与标准化模板制定。
- 综述MVA-BN载体的分子和生物学特征,并提供针对MVA-BN-Filo疫苗的安全性信息收集模板。
主要发现
- MVA-BN在鸡蛋中连续传代超过500次后减毒,显示受限的宿主嗜性且不能在人类细胞中复制。
- MVA有六个主要缺失及缺失外其他基因突变,共同导致在人类和其他哺乳动物细胞中的复制缺陷。
- 多项MVA-BN骨架临床试验中超过7800名参与者接种,安全性与其他现代获批疫苗一致。
- MVA-BN开发全程未发现炎症性心脏疾病信号,而复制型痘苗天花疫苗已知有高达1/200接种者发生心肌炎和/或心包炎的风险。
- MVA-BN-Filo作为异源埃博拉疫苗方案(Ad26.ZEBOV/MVA-BN-Filo)组分已在西非开展III期临床试验,目前在中非国家大规模接种研究中使用。
关键数值与推荐
- MVA-BN于2013年在欧洲和加拿大获批为天花疫苗,2019年在美国获批为天花和猴痘疫苗。
- MVA-BN-Filo于2020年7月在欧盟获批作为异源埃博拉疫苗接种方案的组分。
- 复制型痘苗天花疫苗已知心肌炎和/或心包炎风险高达1/200接种者。
临床怎么用
- 使用MVA-BN载体疫苗时可参照本模板系统收集安全性关键信息以支持风险获益评估。
- MVA-BN-Filo作为异源埃博拉疫苗方案组分已有III期临床测试和规模化接种使用经验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. The Modified Vaccinia Ankara (MVA) vector system is being explored as a platform for development of multiple vaccines. This paper reviews the molecular and biological features specifically of the MVA-BN vector system, followed by a template with details on the safety and characteristics of an MVA-BN based vaccine against Zaire ebolavirus and other filovirus strains. The MVA-BN-Filo vaccine is based on a live, highly attenuated poxviral vector incapable of replicating in human cells and encodes glycoproteins of Ebola virus Zaire, Sudan virus and Marburg virus and the nucleoprotein of the Thai Forest virus. This vaccine has been approved in the European Union in July 2020 as part of a heterologous Ebola vaccination regimen. The MVA-BN vector is attenuated following over 500 serial passages in eggs, showing restricted host tropism and incompetence to replicate in human cells. MVA has six major deletions and other mutations of genes outside these deletions, which all contribute to the replication deficiency in human and other mammalian cells. Attenuation of MVA-BN was demonstrated by safe administration in immunocompromised mice and non-human primates. In multiple clinical trials with the MVA-BN backbone, more than 7800 participants have been vaccinated, demonstrating a safety profile consistent with other licensed, modern vaccines. MVA-BN has been approved as smallpox vaccine in Europe and Canada in 2013, and as smallpox and monkeypox vaccine in the US in 2019. No signal for inflammatory cardiac disorders was identified throughout the MVA-BN development program. This is in sharp contrast to the older, replicating vaccinia smallpox vaccines, which have a known risk for myocarditis and/or pericarditis in up to 1 in 200 vaccinees. MVA-BN-Filo as part of a heterologous Ebola vaccination regimen (Ad26.ZEBOV/MVA-BN-Filo) has undergone clinical testing including Phase III in West Africa and is currently in use in large scale vaccination studies in Central African countries. This paper provides a comprehensive picture of the MVA-BN vector, which has reached regulatory approvals, both as MVA-BN backbone for smallpox/monkeypox, as well as for the MVA-BN-Filo construct as part of an Ebola vaccination regimen, and therefore aims to provide solutions to prevent disease from high-consequence human pathogens.
引用
- Volkmann A, Williamson AL, Weidenthaler H, et al. The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. Vaccine. 2020. PMID: 33077299. doi:10.1016/j.vaccine.2020.08.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。